Open-label, Phase IIIb Study to Evaluate the Efficacy and Safety of Subcutaneous (SC) Tocilizumab Monotherapy or Combination Therapy With Methotrexate (MTX) or Other Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients With Severe Rheumatoid Arthritis (RA) Who Are Being Treated With an Anti-tumour Necrosis Factor (Anti-TNF) Agent and That Have Not Achieved an Adequate Response to Treatment

Trial Profile

Open-label, Phase IIIb Study to Evaluate the Efficacy and Safety of Subcutaneous (SC) Tocilizumab Monotherapy or Combination Therapy With Methotrexate (MTX) or Other Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients With Severe Rheumatoid Arthritis (RA) Who Are Being Treated With an Anti-tumour Necrosis Factor (Anti-TNF) Agent and That Have Not Achieved an Adequate Response to Treatment

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms TOZURA
  • Sponsors Roche
  • Most Recent Events

    • 17 Jun 2017 Results of pooled analysis, presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 01 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 02 Jul 2015 Planned End Date changed from 1 Sep 2016 to 1 Aug 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top